Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Colorcon
Harvard Business School
Merck

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR BRUKINSA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Brukinsa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03145064 ↗ Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma Completed BeiGene Phase 2 2017-06-30 Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.
NCT03332017 ↗ A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma Active, not recruiting BeiGene Phase 2 2017-11-15 The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
NCT03336333 ↗ A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL Recruiting BeiGene Phase 3 2017-11-02 To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.
NCT04002297 ↗ Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma Recruiting BeiGene Phase 3 2019-08-21 This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
NCT04116437 ↗ Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Recruiting BeiGene Phase 2 2019-10-15 The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
NCT04382586 ↗ Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants Completed BeiGene Phase 2 2020-07-06 The primary objective of this study is to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.
NCT04458610 ↗ Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 2020-05-26 This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The study is being done to find out if zanubrutinib combined with rituximab can help control previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brukinsa

Condition Name

Condition Name for Brukinsa
Intervention Trials
Chronic Lymphocytic Leukemia (CLL) 2
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2
Small Lymphocytic Lymphoma 2
Diffuse Large B-cell Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brukinsa
Intervention Trials
Lymphoma 11
Lymphoma, Large B-Cell, Diffuse 4
Lymphoma, B-Cell 4
Leukemia, Lymphoid 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brukinsa

Trials by Country

Trials by Country for Brukinsa
Location Trials
United States 86
China 26
Australia 22
France 14
Japan 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brukinsa
Location Trials
Illinois 6
Texas 6
Nevada 5
Florida 4
Oregon 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brukinsa

Clinical Trial Phase

Clinical Trial Phase for Brukinsa
Clinical Trial Phase Trials
Phase 3 4
Phase 2 10
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brukinsa
Clinical Trial Phase Trials
Recruiting 9
Completed 3
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brukinsa

Sponsor Name

Sponsor Name for Brukinsa
Sponsor Trials
BeiGene 11
Peking Union Medical College Hospital 2
National Cancer Institute (NCI) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brukinsa
Sponsor Trials
Industry 12
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.